Navigation Links
Mylan Reports Third Quarter 2013 Adjusted Diluted EPS of $0.82
Date:10/31/2013

begin to register and download or install any necessary software. A replay of the webcast will be available on www.mylan.com for a limited time.

About MylanMylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

Forward-Looking StatementsThis press release includes statements that constitute "forward-looking statements", including with regard to the Company's future operations, its anticipated business levels, future earnings, planned activities, anticipated growth, and other expectations and targets for future periods. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and often may be identified by the use of words such as "may," "believe," "anticipate," "expect," "plan," "estimate," "target" and variations of these words or comparable words. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking state
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
2. Mylan to Speak at the Morgan Stanley Global Healthcare Unplugged Conference
3. Mylan to Speak at the Bank of America Merrill Lynch Global Healthcare Conference
4. Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vt.
5. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
6. Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
7. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
8. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
9. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
10. Roger Graham Named President of Mylan Specialty
11. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... ... June 29, 2015 , ... Scientists ... approach to build nearly complete genomes by combining high-throughput DNA sequencing with genome ... important for their association with human disease, but previously difficult to detect. The ...
(Date:6/29/2015)... ... ... USA Today reported on June 18th the overdose death rate has ... rest of the nation’s growing overdose death rates in 26 other states the U.S. ... stop the increasing overdose trend from continuing: , , Encourage and ...
(Date:6/29/2015)... ... June 29, 2015 , ... New research released ... than 10 percent of U.S. state and local governments have implemented Next Generation ... deadline for NG9-1-1. , “Mobile phones have surpassed land lines as the ...
(Date:6/29/2015)... Detroit, MI (PRWEB) , ... June 29, 2015 , ... ... offer Kybella™ injection to clients for the reduction of the double chin and redefining ... can cause a person to look much older and heavier causing the person distress ...
(Date:6/29/2015)... New York, NY (PRWEB) , ... June 29, 2015 , ... ... of Radiation Oncology, Care to Care. , Dr. Faber will lead the Radiation Oncology ... complexities of treatment through the use of Care to Care’s proprietary evidence based criteria. ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Overdose Death Rates Decreased in Florida as of 2015 2Health News:Overdose Death Rates Decreased in Florida as of 2015 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 2Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 4Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2Health News:Care to Care, LLC Appoints a New Section Chief of Radiation Oncology 2Health News:Care to Care, LLC Appoints a New Section Chief of Radiation Oncology 3
... a,non-profit organization focused on prevention and recovery from Autism,ADHD ... organization,through three major steps:, 1. Jenny McCarthy, Deirdre ... Ms. McCarthy is a best-selling author, actress, activist, ... latest book, Louder than Words,profiled her own son,s journey ...
... Product That Gives Consumers an All-Natural Cottage Cheese Containing ... ... Beginning in early June, a new,cottage cheese with more healthy ... with Pro-Active,Nutrients. The first to offer this nutrition and health ...
... Management Society of America to Sponsor MEP Workshop at Annual ... ... May 22 The Population Health Impact,Institute (PHII), a non-profit 501(c)(3) ... draft Methods Evaluation,Process(TM) (MEP(TM)) Accreditation Standards. The comment period ends on,July ...
... An experimental drug has blocked the progression of ... form of the disease, new research shows. , The ... called histone deacetylase (HDAC) inhibitors, compounds designed to reactivate ... off by the cancer process. , The study, conducted ...
... that in the dog-eat-dog, look-out-for-No. 1, highly competitive business ... to succeed as an entrepreneur. That statement may sound ... A team led by a University of Missouri researcher ... and women decide to pursue entrepreneurship as a viable ...
... 22 Parks Associates and CEA(R) today,announced ... free pre-show session,at CONNECTIONS(TM) on June 24. ... coalition of the finest healthcare and technology,companies ... quality of,personal healthcare by establishing a system ...
Cached Medicine News:Health News:Generation Rescue to Target Treatment-Based Research for Autism and ADHD - Jenny McCarthy, Deirdre Imus, and Katie Wright Join Board 2Health News:Generation Rescue to Target Treatment-Based Research for Autism and ADHD - Jenny McCarthy, Deirdre Imus, and Katie Wright Join Board 3Health News:New Friendship Cottage Cheese Boosts Digestive & Bone Health 2Health News:New Friendship Cottage Cheese Boosts Digestive & Bone Health 3Health News:Population Health Impact Institute Releases Methods Evaluation Process(TM) (MEP(TM)) Accreditation Standards for Public Comment Period 2Health News:Experimental agent blocks prostate cancer in animal study 2Health News:Taking care of business shouldn't be just for men 2Health News:Continua Health Alliance Provides Insight Into Next Generation of Digital Health at CONNECTIONS(TM) 2
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: